Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Left ventricular ejection fraction 35% assessed by echocardiography, nuclear scan or left ventriculogram within the past 2 years~* Stable (NYHA) class II and III symptoms as defined by:~  1. no change in NYHA symptoms over the past 3 months;~ 2. on stable doses of ACE inhibitor and beta blocker for one month;~ 3. no episode of decompensated CHF over the past 3 months.~* Calculated creatinine clearance of equal or less than 60 ml/min and greater than 30 ml/min, using the Cockcroft-Gault formula assessed within the past 12 months~Exclusion Criteria:~* Nitrates or alpha blockers~* Prior diagnosis of intrinsic renal diseases including renal artery stenosis of \> 50%~* Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period~* Hospitalization for decompensated CHF during the past 3 months~* Myocardial infarction within 3 months of screening~* Unstable angina within 3 months of screening or any evidence of myocardial ischemia~* Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis~* Severe congenital heart diseases~* Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening~* Second or third degree heart block without a permanent cardiac pacemaker~* Stroke within 3 months of screening or other evidence of significantly compromised CNS perfusion~* Serum sodium of \< 125 mEq/dL or \> 150 mEq/dL~* Serum potassium of \< 3.5 mEq/dL or \> 5.7 mEq/dL~* Hemoglobin \< 10 gm/dl~* Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data~* Received an investigational drug within 1 month prior to dosing~* Patients with an allergy to iodine.~* Female subject who is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1: low dose BNP alone (Type: PLACEBO_COMPARATOR): low dose BNP with placebo
- 2: low dose BNP + PDEVI (Type: ACTIVE_COMPARATOR): low dose BNpo + PDEVI

Based on this trial design, predict the completion outcome and termination type (if applicable).